Risperdal Lawsuit Plaintiffs Respond to Defense Bid to Have Some Risperdal Gynecomastia Claims Dismissed on Statute of Limitations Grounds, Bernstein Liebhard LLP Reports

Share Article

The Firm is representing a number of Risperdal lawsuit clients in claims that allege use of the antipsychotic medication caused men and boys to develop gynecomastia (male breast growth).

Free Case Review
Our Firm has filed a number of Risperdal gynecomastia claims in this proceeding. We are monitoring this matter very closely.

Plaintiffs in Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) pending in a mass tort litigation in Pennsylvania’s Philadelphia Court of Common Pleas have responded to a defense motion seeking to have some Risperdal gynecomastia claims dismissed on the grounds that they are time-barred. According to court documents, Johnson & Johnson and its Janssen Pharmaceuticals unit assert that the statutes of limitations governing Risperdal gynecomastia allegations began tolling on October 31, 2006, as plaintiffs were on notice of a potential connection between Risperdal and male breast growth by that date. But in an answer filed with the Court on June 17th, plaintiffs assert, among other things, that the language added to the Risperdal label in October 2006 was not significantly different than previous warnings, and they point out that the companies did not engage in any significant effort to directly warn doctors or patients about the risks of gynecomastia, such as adding a boxed warning to the Risperdal label, or issuing a “Dear Doctor Letter,” to healthcare providers. As such, the answer argues that there was not enough information available in October 2006 regarding gynecomastia to conclude that the statute of limitations for such claims had begun tolling at that time. (Risperdal Litigation, case number 100300296)

“Our Firm has filed a number of Risperdal gynecomastia claims in this proceeding. We are monitoring this matter very closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.

Risperdal Gynecomastia Allegations
Court documents indicate that some 500 Risperdal lawsuits are currently pending in the Pennsylvania proceeding, including hundreds that claim the drug can increase the body’s levels of prolactin, a hormone associated with female breast development and lactation. In men and boys, excess prolactin is associated with excess growth of breast tissue. Among other things, Johnson & Johnson and Janssen are accused of concealing side effects associated with the medication, including the link between Risperdal and gynecomastia. Plaintiffs further allege that the defendants improperly marketed Risperdal for off-label uses, including the treatment of children long before pediatric indications were approved in 2006.

In November 2013, Johnson & Johnson and Janssen agreed to pay $2.2 billion to settle allegations brought against them by the U.S. Department of Justice over the marketing of Risperdal and other medications. Among other things, the government had charged the companies with improperly marketing Risperdal for use in children, and further alleged that they had concealed the link between Risperdal and gynecomastia, as well as other side effects. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and boys who allegedly developed gynecomastia due to their use of Risperdal may be entitled to file their own Risperdal lawsuit. To learn more about Risperdal and gynecomastia, please visit Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website